Market openNon-fractional

Cullinan Oncology/CGEM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Cullinan Oncology

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Ticker

CGEM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

85

CGEM Metrics

BasicAdvanced
$967M
Market cap
-
P/E ratio
-$3.14
EPS
-
Beta
-
Dividend rate
$967M
20.329
19.75
0.432
0.744
-22.15%
-29.47%
1.69
1.69
-5.815
-320.66%
25.84%

What the Analysts think about CGEM

Analyst Ratings

Majority rating from 9 analysts.
Buy

CGEM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$37M
55.88%
Profit margin
0.00%
NaN%

CGEM Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.10%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.82
-$0.91
-$0.54
-$0.86
-
Expected
-$0.97
-$0.92
-$0.96
-$0.99
-$0.73
Surprise
-15.46%
-1.27%
-43.83%
-13.10%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cullinan Oncology stock?

Cullinan Oncology (CGEM) has a market cap of $967M as of July 05, 2024.

What is the P/E ratio for Cullinan Oncology stock?

The price to earnings (P/E) ratio for Cullinan Oncology (CGEM) stock is 0 as of July 05, 2024.

Does Cullinan Oncology stock pay dividends?

No, Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Cullinan Oncology dividend payment date?

Cullinan Oncology (CGEM) stock does not pay dividends to its shareholders.

What is the beta indicator for Cullinan Oncology?

Cullinan Oncology (CGEM) does not currently have a Beta indicator.

Buy or sell Cullinan Oncology stock

Buy or sell Cullinan Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing